Ling-I Hsu

Ling-I Hsu is an epidemiologist with over 10 years of experience specializing in health economics and outcomes research, particularly in Oncology. They have held significant roles, including Associate Director positions at Gilead Sciences and Seagen, focusing on real-world data and the development of Global/US HEOR strategies. Currently, Ling-I serves as the Director of HTA Value and Evidence in Oncology, Precision Medicine, and Lung at Pfizer while pursuing a Ph.D. in Epidemiology at the University of California, Berkeley. They also hold a Master of Public Health from Yale University and a Bachelor's degree in Biochemical Science and Technology from National Taiwan University.